Anifrolumab Treatment Leads to Rapid Reduction in Urinary Biomarkers of Intrarenal Inflammation in Lupus Nephritis: Results From the Phase 2 Randomized Trial
- Journal:
- Arthritis & Rheumatology
- Published:
- DOI:
- 10.1002/art.70089
- Affiliations:
- 5
- Authors:
- 9
| Institutions | Authors | Share |
|---|---|---|
| AstraZeneca UK Limited, United Kingdom (UK) | 0.33 | |
| Johns Hopkins University (JHU), United States of America (USA) | 0.22 | |
| AstraZeneca United States, United States of America (USA) | 0.22 | |
| AstraZeneca Sweden, Sweden | 0.22 |